This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
A Study of LY4257496 in Participants With Cancer (OMNIRAY) | MicrobiomeTrials
← Back to trials NCT07114601
A Study of LY4257496 in Participants With Cancer (OMNIRAY) Recruiting PHASE1 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2025-08-06Est. Completion: 2030-04
Enrollment target: 421 participantsLocations City of Hope, Duarte, California, United States University of California, Los Angeles (UCLA), Santa Monica, California, United States Stanford University Medical Center, Stanford, California, United States Biogenix Molecular, LLC, Miami, Florida, United States Moffitt, Tampa, Florida, United States Emory University School of Medicine - Winship Cancer Institute, Atlanta, Georgia, United States Massachusetts General Hospital, Boston, Massachusetts, United States Dana-Farber Cancer Institute, Boston, Massachusetts, United States Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States BAMF Health Inc., Grand Rapids, Michigan, United States Washington University, St Louis, Missouri, United States New York University (NYU) Langone Medical Center, New York, New York, United States David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York, New York, United States University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States Texas Oncology - DFW (Sammons CC), Dallas, Texas, United States Other microbiome trials you might be interested in Recurrent Breast Carcinoma Stage III Breast Cancer AJCC v7 Stage IIIA Breast Cancer AJCC v7 Stage IIIB Breast Cancer AJCC v7 Stage IIIC Breast Cancer AJCC v7 Stage IV Breast Cancer AJCC v6 and v7
This randomized phase II trial studies how well tamoxifen citrate works compared with z-endoxifen hydrochloride in treat…
Mobile, United States Est. completion Nov 6, 2020
Lymphoplasmacytic Lymphoma
MD Anderson Cancer Center, Houston, Texas, United States
Juravinski Cancer Centre, Hamilton, Canada
Lady Davis Institute for Medical Research Jewish General Hospital, Montreal, Canada
Sunnybrook Health Sciences Centre, Toronto, Canada
Princess Margaret Hospital, Toronto, Canada
Peking Union Medical College Hospital of Chinese Academy of Medical Sciences, Beijing, China
Tianjin Cancer Hospital Airport Hospital, Tianjin, China
Institut Curie, Paris, France
Institut de Cancerologie de l'Ouest - site St-Herblain, Saint-Herblain, France
Universitaetsklinikum Erlangen, Erlangen, Germany
Universitaetsklinikum Essen, Essen, Germany
LMU Klinikum Muenchen-Campus Grosshadern, München, Germany
Klinikum der Technischen Universitaet Muenchen (TUM Klinikum), München, Germany
National Cancer Center Hospital East, Chiba, Japan
Kyoto University Hospital, Kyoto, Japan
The University of Osaka Hospital, Osaka, Japan
Hospital Universitari Quiron Dexeus Barcelona, Barcelona, Spain
South Texas Accelerated Research Therapeutics (START) Madrid - Hospital Fundacion Jimenez Diaz, Madrid, Spain Waldenstrom Macroglobulinemia
This phase II trial studies the effects of venetoclax and rituximab in comparison to ibrutinib and rituximab or zanubrut…
Tucson, United States Est. completion Mar 31, 2028
Pathologic Stage I Cutaneous Merkel Cell Carcinoma AJCC v8 Pathologic Stage II Cutaneous Merkel Cell Carcinoma AJCC v8 Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
This phase III trial studies how well pembrolizumab works compared to standard of care observation in treating patients …
Birmingham, United States Est. completion Dec 31, 2026